search
Back to results

Before-after Comparison of Pharmacist Drug Therapy Management in Pediatric Hypertension

Primary Purpose

Hypertension, Blood Pressure

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Pharmacist Drug Therapy Management
Sponsored by
University of Louisiana Monroe
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for Hypertension focused on measuring Children, Adolescents, Young Adults, Pediatric Hypertension, Pharmacoeconomics, Pharmacist

Eligibility Criteria

4 Years - 20 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria:

  • Diagnosis of elevated blood pressure or hypertension.
  • Physician decision to treat with drug therapy or lifestyle modifications and physician referral to pharmacist.
  • Consent both to therapy with pharmacist and participation in study (Note: in the state of Louisiana, patients must provide consent to be treated in a collaborative drug therapy management program).
  • For patients younger than 18, informed assent and parental permission to participate in the study. For patients who turn 18 during the study, informed consent will be obtained on the first visit after they turn 18.
  • Males and females; age 4-20 at enrollment
  • Willingness to adhere to study regimen

The same inclusion criteria will apply to control patients except that:

  • They will have been treated at the clinic for hypertension or elevated blood pressure during the control period.
  • A waiver of consent has been obtained for historical data.

Exclusion Criteria:

  • Physical preclusion to taking blood pressure, such as lack of limbs or any congenital or acquired anatomical defect preventing routine measurement of blood pressure
  • Participation in another treatment or intervention study for hypertension during the study period
  • Inability to speak English
  • For patients under 18 years old, not having at least one parent or guardian able to speak English
  • Patients who are pregnant

Sites / Locations

  • Ochsner Health Center for Children

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Pharmacist Drug Therapy Management

Arm Description

Outcomes

Primary Outcome Measures

Proportion of patients with adequately-controlled hypertension at 3 months.
Proportion of patients with adequately-controlled hypertension at 6 months.
Proportion of patients with adequately-controlled hypertension at 12 months.
Time to adequate control of hypertension.
Defined as the first appointment with controlled hypertension.

Secondary Outcome Measures

Appointment adherence
Proportion of appointments attended
Number and type of serious adverse drug events
Number of serious adverse drug events in aggregate and subgrouped.
Number of unplanned health care encounters related to hypertension
Surrogate for adverse event associated with treatment or disease state.
Costs to patients
Includes direct medical, direct nonmedical, indirect costs
Costs to communities
Includes healthcare resource utilization, lost productivity
Cost to healthcare systems and payors

Full Information

First Posted
September 18, 2019
Last Updated
June 2, 2022
Sponsor
University of Louisiana Monroe
Collaborators
Ochsner Health System
search

1. Study Identification

Unique Protocol Identification Number
NCT04098978
Brief Title
Before-after Comparison of Pharmacist Drug Therapy Management in Pediatric Hypertension
Official Title
Before-after Comparison of Pharmacist Drug Therapy Management in Pediatric Hypertension
Study Type
Interventional

2. Study Status

Record Verification Date
June 2022
Overall Recruitment Status
Completed
Study Start Date
January 14, 2020 (Actual)
Primary Completion Date
December 31, 2021 (Actual)
Study Completion Date
December 31, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Louisiana Monroe
Collaborators
Ochsner Health System

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study will measure the effect of a novel pharmacy practice model on pediatric patients with hypertension. In North Louisiana, many patients have to travel to see subspecialists for treatment for hypertension and elevated blood pressure, which has many costs including direct medical costs, direct nonmedical costs, and indirect costs like missed time from work, school, or social obligations. Also, many patients who have to travel to get to their appointments have a high rate of missed appointments, which can be bad for overall health. This study will use a pharmacist to perform collaborative drug therapy management with pediatric cardiologists to manage therapy for patients with hypertension or elevated blood pressure. Patients will monitor blood pressure at home and follow up with the pharmacist by telecommunications. Pharmacist drug therapy management and telemedicine have been studied separately, but this is the first study with pharmacist drug therapy management by telemedicine for pediatric patients. If this model is successful, it could be replicated in other rural areas to improve patient care and reduce healthcare costs.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension, Blood Pressure
Keywords
Children, Adolescents, Young Adults, Pediatric Hypertension, Pharmacoeconomics, Pharmacist

7. Study Design

Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Before-after comparison of intervention to traditional care
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
266 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Pharmacist Drug Therapy Management
Arm Type
Experimental
Intervention Type
Other
Intervention Name(s)
Pharmacist Drug Therapy Management
Intervention Description
Patients will be seen by pharmacist for collaborative drug therapy management.
Primary Outcome Measure Information:
Title
Proportion of patients with adequately-controlled hypertension at 3 months.
Time Frame
3 months
Title
Proportion of patients with adequately-controlled hypertension at 6 months.
Time Frame
6 months
Title
Proportion of patients with adequately-controlled hypertension at 12 months.
Time Frame
12 months
Title
Time to adequate control of hypertension.
Description
Defined as the first appointment with controlled hypertension.
Time Frame
Through study completion, an average of 1 year.
Secondary Outcome Measure Information:
Title
Appointment adherence
Description
Proportion of appointments attended
Time Frame
Through study completion, an average of 1 year.
Title
Number and type of serious adverse drug events
Description
Number of serious adverse drug events in aggregate and subgrouped.
Time Frame
Through study completion, an average of 1 year.
Title
Number of unplanned health care encounters related to hypertension
Description
Surrogate for adverse event associated with treatment or disease state.
Time Frame
Through study completion, an average of 1 year.
Title
Costs to patients
Description
Includes direct medical, direct nonmedical, indirect costs
Time Frame
Through study completion, an average of 1 year.
Title
Costs to communities
Description
Includes healthcare resource utilization, lost productivity
Time Frame
Through study completion, an average of 1 year.
Title
Cost to healthcare systems and payors
Time Frame
Through study completion, an average of 1 year.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
4 Years
Maximum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria: Diagnosis of elevated blood pressure or hypertension. Physician decision to treat with drug therapy or lifestyle modifications and physician referral to pharmacist. Consent both to therapy with pharmacist and participation in study (Note: in the state of Louisiana, patients must provide consent to be treated in a collaborative drug therapy management program). For patients younger than 18, informed assent and parental permission to participate in the study. For patients who turn 18 during the study, informed consent will be obtained on the first visit after they turn 18. Males and females; age 4-20 at enrollment Willingness to adhere to study regimen The same inclusion criteria will apply to control patients except that: They will have been treated at the clinic for hypertension or elevated blood pressure during the control period. A waiver of consent has been obtained for historical data. Exclusion Criteria: Physical preclusion to taking blood pressure, such as lack of limbs or any congenital or acquired anatomical defect preventing routine measurement of blood pressure Participation in another treatment or intervention study for hypertension during the study period Inability to speak English For patients under 18 years old, not having at least one parent or guardian able to speak English Patients who are pregnant
Facility Information:
Facility Name
Ochsner Health Center for Children
City
West Monroe
State/Province
Louisiana
ZIP/Postal Code
71292
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
De-identified IPD will be available to researchers within the University of Louisiana Monroe based on IRB review and approval.
IPD Sharing Time Frame
Upon completion of study.
Citations:
PubMed Identifier
23543372
Citation
Syed ST, Gerber BS, Sharp LK. Traveling towards disease: transportation barriers to health care access. J Community Health. 2013 Oct;38(5):976-93. doi: 10.1007/s10900-013-9681-1.
Results Reference
background
PubMed Identifier
27933188
Citation
Stumetz KS, Yi-Frazier JP, Mitrovich C, Briggs Early K. Quality of care in rural youth with type 1 diabetes: a cross-sectional pilot assessment. BMJ Open Diabetes Res Care. 2016 Nov 24;4(1):e000300. doi: 10.1136/bmjdrc-2016-000300. eCollection 2016.
Results Reference
background
PubMed Identifier
29354549
Citation
Dalton K, Byrne S. Role of the pharmacist in reducing healthcare costs: current insights. Integr Pharm Res Pract. 2017 Jan 25;6:37-46. doi: 10.2147/IPRP.S108047. eCollection 2017.
Results Reference
background
PubMed Identifier
27605321
Citation
Hawes EM, Misita C, Burkhart JI, McKnight L, Deyo ZM, Lee RA, Howard C, Eckel SF. Prescribing pharmacists in the ambulatory care setting: Experience at the University of North Carolina Medical Center. Am J Health Syst Pharm. 2016 Sep 15;73(18):1425-33. doi: 10.2146/ajhp150771.
Results Reference
background
PubMed Identifier
28775188
Citation
Kruse CS, Krowski N, Rodriguez B, Tran L, Vela J, Brooks M. Telehealth and patient satisfaction: a systematic review and narrative analysis. BMJ Open. 2017 Aug 3;7(8):e016242. doi: 10.1136/bmjopen-2017-016242.
Results Reference
background
PubMed Identifier
29527973
Citation
Victor RG, Lynch K, Li N, Blyler C, Muhammad E, Handler J, Brettler J, Rashid M, Hsu B, Foxx-Drew D, Moy N, Reid AE, Elashoff RM. A Cluster-Randomized Trial of Blood-Pressure Reduction in Black Barbershops. N Engl J Med. 2018 Apr 5;378(14):1291-1301. doi: 10.1056/NEJMoa1717250. Epub 2018 Mar 12.
Results Reference
background
PubMed Identifier
27873322
Citation
Weeks G, George J, Maclure K, Stewart D. Non-medical prescribing versus medical prescribing for acute and chronic disease management in primary and secondary care. Cochrane Database Syst Rev. 2016 Nov 22;11(11):CD011227. doi: 10.1002/14651858.CD011227.pub2.
Results Reference
background
PubMed Identifier
21768583
Citation
Berkman ND, Sheridan SL, Donahue KE, Halpern DJ, Crotty K. Low health literacy and health outcomes: an updated systematic review. Ann Intern Med. 2011 Jul 19;155(2):97-107. doi: 10.7326/0003-4819-155-2-201107190-00005.
Results Reference
background
PubMed Identifier
28827377
Citation
Flynn JT, Kaelber DC, Baker-Smith CM, Blowey D, Carroll AE, Daniels SR, de Ferranti SD, Dionne JM, Falkner B, Flinn SK, Gidding SS, Goodwin C, Leu MG, Powers ME, Rea C, Samuels J, Simasek M, Thaker VV, Urbina EM; SUBCOMMITTEE ON SCREENING AND MANAGEMENT OF HIGH BLOOD PRESSURE IN CHILDREN. Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. Pediatrics. 2017 Sep;140(3):e20171904. doi: 10.1542/peds.2017-1904. Epub 2017 Aug 21. Erratum In: Pediatrics. 2017 Nov 30;: Pediatrics. 2018 Sep;142(3):
Results Reference
background
PubMed Identifier
18559702
Citation
Chen X, Wang Y. Tracking of blood pressure from childhood to adulthood: a systematic review and meta-regression analysis. Circulation. 2008 Jun 24;117(25):3171-80. doi: 10.1161/CIRCULATIONAHA.107.730366. Epub 2008 Jun 16.
Results Reference
background
PubMed Identifier
29192011
Citation
Flynn JT, Kaelber DC, Baker-Smith CM, et al; SUBCOMMITTEE ON SCREENING AND MANAGEMENT OF HIGH BLOOD PRESSURE IN CHILDREN. Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. Pediatrics. 2017; 140(3):e20171904. Pediatrics. 2017 Dec;140(6):e20173035. doi: 10.1542/peds.2017-3035. No abstract available.
Results Reference
background
PubMed Identifier
23821088
Citation
Margolis KL, Asche SE, Bergdall AR, Dehmer SP, Groen SE, Kadrmas HM, Kerby TJ, Klotzle KJ, Maciosek MV, Michels RD, O'Connor PJ, Pritchard RA, Sekenski JL, Sperl-Hillen JM, Trower NK. Effect of home blood pressure telemonitoring and pharmacist management on blood pressure control: a cluster randomized clinical trial. JAMA. 2013 Jul 3;310(1):46-56. doi: 10.1001/jama.2013.6549.
Results Reference
background
PubMed Identifier
28483010
Citation
Twigg G, Motsko J, Thomas J, David T. Pharmacist-Managed Diabetes Center Interventions Ensure Quality and Safety in Elderly Patients. Consult Pharm. 2017 May 1;32(5):299-310. doi: 10.4140/TCP.n.2017.299.
Results Reference
background

Learn more about this trial

Before-after Comparison of Pharmacist Drug Therapy Management in Pediatric Hypertension

We'll reach out to this number within 24 hrs